Tetraphase Pharmaceuticals, Inc. (TTPH)
| Market Cap | 16.07M |
| Revenue (ttm) | 7.86M |
| Net Income (ttm) | n/a |
| Shares Out | 7.26M |
| EPS (ttm) | -13.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Jul 28, 2020 |
| Last Price | $2.20 |
| Previous Close | $2.20 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 2.18 - 2.27 |
| Day's Volume | 0 |
| 52-Week Range | 0.56 - 8.60 |
News
As the virus spreads, if you’re looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence (“AI”) data has some Top Shorts named for you t...
We will have to wait to see if the wind is truly changing to the bears, or if the bulls can come back throughout the day – either way, our deep learning algorithms paired with Artificial Intel...
SAN DIEGO & WATERTOWN, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in pat...
The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) seems to be far from over.
WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for inje...
With the S&P 500, Nasdaq, and Dow going positive today, we link the markets are overextended. Our deep learning and AI has identified several Top Shorts today for you to hedge your portfolio w...
This week has been a successful one for markets, with the S&P 500 entering positive territory on the year. If you’re looking to hedge the rally, our deep learning algorithms have identified se...
Tetraphase (TTPH) delivered earnings and revenue surprises of 19.63% and -28.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thu...
Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.
Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tetraphase Pharmaceuticals, Inc. (TTPH) CEO Larry Edwards on Q3 2019 Results - Earnings Call Transcript
Tetraphase (TTPH) delivered earnings and revenue surprises of 4.31% and 115.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Tetraphase Pharmaceuticals, Inc. (TTPH) CEO Larry Edwards on Q2 2019 Results - Earnings Call Transcript
Tetraphase (TTPH) delivered earnings and revenue surprises of -10.53% and -49.62%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tetraphase Pharmaceuticals' (TTPH) CEO Guy Macdonald on Q1 2019 Results - Earnings Call Transcript
Tetraphase (TTPH) delivered earnings and revenue surprises of 7.69% and -34.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Tetraphase Pharmaceuticals, Inc. (TTPH) CEO Guy Macdonald on Q4 2018 Results - Earnings Call Transcript
About TTPH
Tetraphase Pharmaceuticals, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGN... [Read more...]
| Industry Biotechnology | IPO Date Mar 20, 2013 |
| CEO Larry Edwards | Employees 67 |
| Stock Exchange NASDAQ | Ticker Symbol TTPH |
Financial Performance
In 2019, TTPH's revenue was $7.38 million, a decrease of -60.98% compared to the previous year's $18.90 million. Losses were -$70.09 million, -2.87% less than in 2018.